Authors: Jonas P DeMuro David G Botros Ela Wirkowski Adel F Hanna
Publish Date: 2012/05/15
Volume: 26, Issue: 4, Pages: 601-605
Abstract
Alcohol withdrawal syndrome AWS continues to be a challenge to manage in the ICU setting and the ideal pharmacological treatment continues to evolve Dexmedetomidine is a newer agent approved for shortterm sedation in the ICU but its use in the treatment of AWS has been limited We report a retrospective case series of ten patients who were identified as receiving dexmedetomidine for AWS as designated by electronic pharmacy records All subjects were male with a mean age of 536 years and a mean ICU length of stay of 93 days They were all diagnosed with AWS by DSMIV criteria All the study patients received dexmedetomidine during their hospital course as a treatment for AWS Studied variables included demographic data dose and duration of dexmedetomidine other pharmaceutical agents and hemodynamics Dexmedetomidine was safe to use in all patients although mechanical ventilation was still required in three patients With dexmedetomidine the autonomic hyperactivity was blunted with a mean 128 reduction in rate pressure product observed Consideration should be given to the combined use of dexmedetomidine with benzodiazepines in the treatment of AWS
Keywords: